Pricing Log in Create free account

Immunome, Inc. (IMNM) vs Replimune Group, Inc. (REPL)

Immunome, Inc. and Replimune Group, Inc. are both Biotechnology companies. Immunome, Inc. and Replimune Group, Inc. are of similar size ($2.2B and $2.2B). Across the 11 metrics below, Immunome, Inc. leads on 8 and Replimune Group, Inc. on 3.

Valuation

Metric IMNM REPL Biotechnology median
P/E n/m n/m 11.58
P/S 172.39 n/m 9.61
P/B 4.78 11.24 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 135.77 n/m 9.43
Earnings yield (13.79%) (12.77%) (32.28%)
Free cash flow yield (11.00%) (10.68%) (22.27%)

Profitability

Metric IMNM REPL Biotechnology median
Gross margin 100.00% 0.00% 68.81%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (78.71%) (115.80%) (50.30%)
Return on assets (70.23%) (71.01%) (45.47%)
Return on invested capital 0.00% (928.27%) 0.00%

Growth

Metric IMNM REPL Biotechnology median
Revenue growth (TTM) 16.74% — 6.78%
EPS growth (last fiscal year) 51.40% (10.10%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMNM REPL Biotechnology median
Debt to equity 0.00 0.59 0.00
Current ratio 11.66 7.11 4.74
Net debt to EBITDA 2.92 0.51 1.01

Dividend

Metric IMNM REPL Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric IMNM REPL Biotechnology median
Market cap 2.20b 2.21b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack